mRNA-4157/V940: The Personalized Cancer Vaccine Rewriting the Rules of Oncology
mRNA-4157/V940, a personalized neoantigen therapy developed by Moderna and Merck, has demonstrated a 44% reduction in re...
Read More →Market and economic updates.
mRNA-4157/V940, a personalized neoantigen therapy developed by Moderna and Merck, has demonstrated a 44% reduction in re...
Read More →The p-tau217 blood biomarker test has revolutionized Alzheimer’s diagnosis, offering over 90% accuracy and replacing c...
Read More →Pfizer and BioNTech have acquired Catalent’s biologics division for $14B to secure the critical manufacturing capacity...
Read More →Lockheed Martin and SpaceX have secured a $35B joint contract to build the Cislunar Logistics Network, merging defense e...
Read More →NextEra Energy has signed a historic $22B Power Purchase Agreement with tech giants to finance the construction of dedic...
Read More →The European Commission has levied a $6B antitrust fine on the Hyperscaler Consortium for colluding to restrict AI compu...
Read More →Blackstone has acquired a $30B portfolio of data center real estate from Digital Realty Trust, marking a massive institu...
Read More →JPMorgan Chase has launched Project Aegis, Wall Street’s first quantum-resistant institutional trading platform, utili...
Read More →Toyota has formed a $25B joint venture with Panasonic and BHP to secure sodium and sulfur supply chains for its 1,200-mi...
Read More →Walmart's Q2 earnings shattered expectations, driven by a surge in consumer discretionary spending following the collaps...
Read More →